Pulmonary Fibrosis: future focus for developing novel treatments
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive pathology which leads to a gradual loss of pulmonary function. The pathology is characterised by accumulation of fibrotic tissue due to abnormal ECM remodelling. Currently, the market only offers therapies targeting the symptoms, rather than the causes, which are largely unknown.
However, there is growing evidence of a link between the pathogenesis of IPF and COPD, which with the projected higher numbers of patients affected, could increase the industry’s interest in finding treatments for the causes of both.
Our free report, "Pulmonary Fibrosis: future focus for developing novel treatments" covers
- Current treatment options
- Targets and current pipeline
- Today's discovery tools
- Development of novel compounds - the road ahead